Gold prices head for highest finish in over 2 weeks
Gold prices moved higher on Monday, on track to settle at their highest in just over two weeks after touching an intraday high of $2,700 an ounce.
All Posts in "News Team"
Nvidia Drags Wall Street From Its Records as Oil and Gold Rise
A slide for market superstar Nvidia helped pull U.S. stock indexes down from their records
HealthEquity Shares Fall After Outlook for Next Fiscal Year Missed Expectations
Shares of HealthEquity dropped after the company’s outlook for the next fiscal year missed Wall Street expectations.
Embecta secures FDA clearance for insulin patch pump in Type 1 and Type 2 diabetes
Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes.
Vaxcyte’s ‘stunning’ 31-valent pneumococcal vaccine win against Pfizer’s Prevnar 20 has analysts thinking big
Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate that, if replicated in a large pivotal study, could pose a serious threat to Pfizer’s stalwart Prevnar 20.
EU high court hands Illumina consolation prize, ruling in favor of its appeal over Grail
Though Illumina said goodbye to Grail this past summer—after butting heads for years with antitrust regulators and activist investors, while enduring heavy fines and orders to split—the European Union’s highest court now says the company may have had a point from the beginning.
Praxis’ sodium channel blocker reduces seizures in 2 types of epilepsy in phase 2
Praxis Precision Medicines has scored another midphase win in epilepsy this year, with its sodium channel inhibitor shown to reduce seizures in children with two specific types of the neurological disorder.
Recursion’s phase 2 brain disease trial yields scant evidence of efficacy
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the efficacy front.
Acepodia and Pfizer Ignite click together to advance chemistry-based cell therapies
Call it a case of good chemistry: Acepodia, a biotech based on Nobel Prize-winning science, is entering into a new partnership with Pfizer’s Ignite program to support development of the biotech’s unique cell immunotherapies.
Aixial Group adopts Medidata’s platform to consolidate clinical trial data
France-based clinical research company Aixial Group is consolidating clinical data from one of its business units into Medidata’s digital platform, according to a Sept. 3 release.
Drug based on anti-nausea agent reduces Alzheimer’s-advancing astrocytes in mice, biotech says
FDA elevates recall as Zimmer Biomet phases out hip replacement implant
Alkeus’ oral eye disease asset fails to significantly reduce lesion growth in phase 3
Rakovina deepens AI focus with cancer collab to select DNA-damage response kinase targets
FDA clears Senseonics’ 365-day Eversense CGM implant
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
Ascendis’ dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
Trispecific antibody from Ichnos Glenmark Innovation beats J&J’s Tecvayli at treating multiple myeloma in mice
American Consumers Feeling Less Confident in December, Conference Board Says
Biden Will Decide on US Steel Acquisition After Influential Panel Fails to Reach Consensus